Jun 10, 2020 - MYR Pharmaceuticals has incorporated its first European subsidiary in France.
May 29, 2020 - MYR Pharmaceuticals receives positive CHMP opinion for HEPCLUDEX® (bulevirtide), the First-in-Class Entry Inhibitor for the treatment of chronic hepatitis D infections.
April 14, 2019 - Interview. Prof. Dr. Med. Heiner Wedemeyer. The International Liver Congress 2019.
April 13, 2019 - ILC 2019: First-in-class entry inhibitor bulevirtide (Myrcludex B) effective and well tolerated in combination with PEG-IFN-a in Phase 2b study involving individuals with chronic hepatitis B/D virus coinfection, producing high rates of viral suppression both on and off treatment with good tolerability.
April 12, 2019 - EASL Press Conference 2019. The International Liver Congress 2019.
April 04, 2019 - MYR Pharmaceuticals Announces Presentation of Final Results of the MYR203 Study of bulevirtide (Myrcludex) at the International Liver Congress (ILC) 2019 in Vienna.
March 05, 2019 - MYR Pharma Announces Grant of Promising Innovative Medicine (PIM) Designation by British MHRA for Bulevirtide (Myrcludex), the First-in-Class Entry Inhibitor for Treatment of Chronic Hepatitis D Infections
October 29, 2018 - MYR Pharma Announces Presentation of Interim Results of MYR 203, a Phase 2 Study of Myrcludex in Combination with Pegylated Interferon in Chronic Hepatitis Delta
October 23, 2018 - MYR Pharma Announces Grant of Breakthrough Therapy Designation by US FDA for Myrcludex, the First-in-Class Entry Inhibitor for Treatment of chronic Hepatitis B and D Infections
March 27, 2018 - MYR Pharma Announces Multiple Presentations at the European Association for the Study of the Liver (EASL) Meeting
March 12, 2018 - MYR Pharma Completes MYR 202 Clinical Trial of Myrcludex B in Chronic Hepatitis Delta
February 22, 2018 - MYR Pharma Announces Completion of Active Treatment Phase in MYR 203 Clinical Trial of Myrcludex B
October 22, 2017 - MYR Pharma presents positive interim results in MYR 202 clinical trial
July - September, 2017 – Several review articles highlight Myrcludex B as a strong contender in the treatment of Hepatitis D and B:
- Kaufmann, S.H., Dorhoi, A., Hotchkiss, R.S. and Bartenschlager, R., 2018. Host-directed therapies for bacterial and viral infections. Nature Reviews Drug Discovery, 17(1), p.35.
- Lempp, F.A. and Urban, S., 2017. Hepatitis Delta Virus: Replication Strategy and Upcoming Therapeutic Options for a Neglected Human Pathogen. Viruses, 9(7), p.172.
- Rizzetto, M., 2017. Investigational drugs in development for hepatitis D. Expert opinion on investigational drugs, 26(9), pp.999-1005.
May 26, 2017 – Myrcludex B becomes one of five new drugs to receive PRIME (PRIority MEdicines) designation in 2017
May 2, 2017 – Myrcludex B potential in the treatment of Hepatitis D reviewed in Current Opinion in Virology
May 25, 2016 – Initiation of MYR 203
April 24, 2016 - First results of chronic Hepatitis D treatment with Myrcludex B are published in Journal of Hepatology
April 24, 2016 – Results of first-in-human application of Myrcludex B are reported in Jounral of Hepatology